Apyx Medical Corporation (APYX)
| Market Cap | 374.28M |
| Revenue (ttm) | 24.71M |
| Net Income (ttm) | -16.18M |
| Shares Out | 34.22M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $10.92 |
| Previous Close | $10.40 |
| Change ($) | 0.52 |
| Change (%) | 5.00% |
| Day's Open | 10.32 |
| Day's Range | 10.32 - 11.01 |
| Day's Volume | 113,565 |
| 52-Week Range | 2.81 - 11.79 |
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).
Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2020 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q3 results.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2020 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 17.65% and 71.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q2 results.
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
NEW YORK, July 30, 2020 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of ...
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and s...
PHILADELPHIA, June 6, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company's stock...
NEW YORK, May 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corpora...
Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
As of late, it has definitely been a great time to be an investor of Apyx Medical
Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q1 2020 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q4 2019 Results - Earnings Call Transcript
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for November 21st
Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2019 Results - Earnings Call Transcript
Apyx (APYX) delivered earnings and revenue surprises of 27.78% and 13.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apyx Medical Corp (APYX) CEO Charlie Goodwin on Q2 2019 Results - Earnings Call Transcript
Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apyx Medical Corporation's (APYX) CEO Charlie Goodwin on Q1 2019 Results - Earnings Call Transcript
Apyx Medical (APYX) likely to gain from J-plasma technology in Q1; margins under pressure.
About APYX
Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renu... [Read more...]
| Industry Medical Devices | IPO Date Jan 1, 1987 |
| CEO Charles Goodwin | Employees 266 |
| Stock Exchange NASDAQ | Ticker Symbol APYX |
Analyst Forecasts
According to 4 analysts, the average rating for Apyx Medical stock is "Buy." The 12-month stock price forecast is 12.50, which is an increase of 14.47% from the latest price.